Articles by Regina Barragan-Carrillo, MD
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Dr. Barragán-Carrillo explains the potential benefits of camu camu in reducing tumor size.
Dr. Regina Barragán-Carrillo discusses new data in the IO-refractory RCC setting that were presented during the RCC panel.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.